Works by Omar, Zaayid

Results: 5

Virologic outcomes with tenofovir-lamivudinedolutegravir in adults failing PI-based second-line ART.
Published in:
Southern African Journal of HIV Medicine, 2024, v. 25, n. 1, p. 1, doi. 10.4102/sajhivmed.v25i1.1567
By:
- Zhao, Ying;
- Voget, Jacqueline;
- Singini, Isaac;
- Omar, Zaayid;
- Mudaly, Vanessa;
- Boulle, Andrew;
- Maartens, Gary;
- Meintjes, Graeme
Publication type:
Article
INITIAL SUPPLEMENTAL DOLUTEGRAVIR DOSE IN SECOND-LINE ART: A PHASE 2 RANDOMISED TRIAL.
Published in:
Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 206
By:
- Ying Zhao;
- Griesel, Rulan;
- Omar, Zaayid;
- Simmons, Bryony;
- Hill, Andrew;
- van Zyl, Gert;
- Keene, Claire;
- Maartens, Gary;
- Meintjes, Graeme
Publication type:
Article
PHARMACOKINETICS OF STANDARD VS DOUBLE-DOSE DOLUTEGRAVIR AFTER SWITCH FROM EFAVIRENZ.
Published in:
Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 199
By:
- Griesel, Rulan;
- Banda, Clifford;
- Zhao, Ying;
- Sinxadi, Phumla;
- Omar, Zaayid;
- Meintjes, Graeme;
- Maartens, Gary
Publication type:
Article
STANDARD VS DOUBLE DOSE DOLUTEGRAVIR IN HIV-ASSOCIATED TUBERCULOSIS: WEEK 48 RESULTS.
Published in:
Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 45
By:
- Griesel, Rulan;
- Ying Zhao;
- Simmons, Bryony;
- Omar, Zaayid;
- Hill, Andrew;
- Meintjes, Graeme;
- Maartens, Gary
Publication type:
Article
Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.
Published in:
Clinical Infectious Diseases, 2023, v. 76, n. 10, p. 1832, doi. 10.1093/cid/ciad023
By:
- Zhao, Ying;
- Griesel, Rulan;
- Omar, Zaayid;
- Simmons, Bryony;
- Hill, Andrew;
- Zyl, Gert van;
- Keene, Claire;
- Maartens, Gary;
- Meintjes, Graeme
Publication type:
Article

Works by Omar, Zaayid

Virologic outcomes with tenofovir-lamivudinedolutegravir in adults failing PI-based second-line ART.

INITIAL SUPPLEMENTAL DOLUTEGRAVIR DOSE IN SECOND-LINE ART: A PHASE 2 RANDOMISED TRIAL.

PHARMACOKINETICS OF STANDARD VS DOUBLE-DOSE DOLUTEGRAVIR AFTER SWITCH FROM EFAVIRENZ.

STANDARD VS DOUBLE DOSE DOLUTEGRAVIR IN HIV-ASSOCIATED TUBERCULOSIS: WEEK 48 RESULTS.

Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.